<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although diet and exercise remain the cornerstones of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> therapy, attempts at lifestyle changes seldom result in the achievement of glycaemic control </plain></SENT>
<SENT sid="1" pm="."><plain>As a result, the addition of pharmacological agents is usually necessary </plain></SENT>
<SENT sid="2" pm="."><plain>Currently available treatment options improve glycaemic control in the short term; however, maintaining long-term glycaemic control, halting disease progression, and preventing the complications of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> have <z:hpo ids='HP_0000001'>all</z:hpo> proven to be elusive therapeutic goals </plain></SENT>
<SENT sid="3" pm="."><plain>For more than 30 years, sulphonylureas (SUs) have been first-line therapy for the management of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>These compounds control <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> by stimulating insulin release from pancreatic beta cells, and thus their benefits are limited to patients with preserved beta-cell function </plain></SENT>
<SENT sid="5" pm="."><plain>Despite historic reliance on these agents to treat type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, long-term use of SUs may desensitize beta cells </plain></SENT>
<SENT sid="6" pm="."><plain>The meglitinides (e.g. repaglinide) are a new class of non-sulphonylurea secretagogues that bind to a different receptor on the beta cell </plain></SENT>
<SENT sid="7" pm="."><plain>Repaglinide has a short duration of action and may be useful for the treatment of postprandial <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The <z:chebi fb="0" ids="3095">biguanides</z:chebi> (e.g. <z:chebi fb="0" ids="6801">metformin</z:chebi>) represent another class of <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agents and improve glycaemic control primarily by decreasing hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> output </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> and SUs provide similar <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering effects, and, in combination, may provide additional benefits in some patients </plain></SENT>
<SENT sid="10" pm="."><plain>Reducing the rate of <z:chebi fb="105" ids="17234">glucose</z:chebi> absorption with alpha-glucosidase inhibitors (e.g. <z:chebi fb="0" ids="2376">acarbose</z:chebi>) has been explored as an alternative approach to the management of postprandial <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, but these agents do not address the primary defect in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>Eventually, prolonged overproduction of insulin to compensate for <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> leads to dramatically reduced beta-cell function, and exogenous insulin therapy is required </plain></SENT>
</text></document>